Nicolas Lechevalier
YOU?
Author Swipe
View article: How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears
How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears Open
International audience
View article: Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study Open
View article: Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study. Open
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little da…
View article: Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy
Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy Open
Background Acute myeloid leukemia (AML) with myelodysplasia‐related characteristics is a heterogeneous subset of AML that has been challenged throughout the history of myeloid malignancies classifications, considered to have similar outcom…
View article: Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia Open
Risk stratification and treatment response evaluation are key features in acute myeloid leukemia (AML) management. Immunophenotypic and molecular approaches all rely on the detection of persisting leukemic cells by measurable residual dise…
View article: Prognostic value of post-induction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
Prognostic value of post-induction medullary myeloid recovery by flow cytometry in acute myeloid leukemia Open
Risk stratification and treatment response evaluation are key features in acute myeloid leukemia (AML) management. Immunophenotypic and molecular approaches all rely on the detection of persisting leukemic cells by measurable residual dise…
View article: Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Supplemental figure 1. Flow chart for sample availability of patients included in our study and their outcome. Supplemental figure 2. Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- population…
View article: Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Supplemental figure 1. Flow chart for sample availability of patients included in our study and their outcome. Supplemental figure 2. Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- population…
View article: Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Ta…
View article: Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Ta…
View article: Data from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Data from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Purpose:Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) that carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating the clinical relevance of LS…
View article: Data from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Data from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia Open
Purpose:Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) that carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating the clinical relevance of LS…
View article: The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significance
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significance Open
Myelodysplastic syndromes (MDS) are hematological malignancies classically defined by the presence of cytopenia(s) and dysmorphic myeloid cells. It is now known that MDS can be preceded by a pre‐malignant condition called clonal cytopenia …
View article: Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia Open
View article: An unusual case of cytoplasmic <scp>CD3</scp> expressing <scp>BPDCN</scp> supporting the T‐lineage origin of plasmacytoid dendritic cells
An unusual case of cytoplasmic <span>CD3</span> expressing <span>BPDCN</span> supporting the T‐lineage origin of plasmacytoid dendritic cells Open
A 36-year-old woman, without medical history, presented bone pain and impaired general condition. CBC showed 4.7 g/dL anemia and 8.6 G/L white blood cells (WBC) including 19% blast cells. Bone marrow (BM) was massively infiltrated by blast…
View article: Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes Open
View article: Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia Open
The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients wh…
View article: Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome Open
Postremission treatment is crucial to prevent relapse in acute myeloid leukemia (AML). High-dose cytarabine delivered every 12 hours on days 1, 3, and 5 (HDAC-135) is the standard of care for younger adult patients with AML. Although this …
View article: Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study Open
Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the c…
View article: Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study Open
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared…
View article: How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (…
View article: An R‐Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data
An R‐Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data Open
Multiparameter flow cytometry (MFC) is a powerful and versatile tool to accurately analyze cell subsets, notably to explore normal and pathological hematopoiesis. Yet, mostly supervised subjective strategies are used to identify cell subse…
View article: PS1234 APPLICATION OF FLOW SOM TO CLASSICAL FLOW CYTOMETRY: UNSUPERVISED ANALYSIS OF HEMATOPOIESIS AND HEMATOLOGICAL MALIGNANCIES
PS1234 APPLICATION OF FLOW SOM TO CLASSICAL FLOW CYTOMETRY: UNSUPERVISED ANALYSIS OF HEMATOPOIESIS AND HEMATOLOGICAL MALIGNANCIES Open
Background: Multiparameter flow cytometry (MFC) is an essential tool for the diagnosis and follow‐up of hematological malignancies. Numerous panels have been devised that best allow to achieve these goals. However, analysis of MFC graphs s…
View article: Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning
Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning Open
Supplemental Digital Content is available in the text
View article: Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm
Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm Open
A 74-year-old patient was hospitalised for the investigation of generalised lymphadenopathy and cutaneous manifestations (red and inflammatory nodules, erythema in 12 different localizations) 2 years after a diagnosis of chronic myelomonoc…
View article: Innovation in Flow Cytometry Analysis
Innovation in Flow Cytometry Analysis Open
View article: B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia
B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia Open
![Figure][1]
A 59-year-old woman was hospitalized for investigation of spontaneous bruises on arms and legs and asthenia. Complete blood count and blood smear review showed pancytopenia (platelets 78 × 109/L, hemoglobin concentration 10.…
View article: Reference Values for WBC Differential by Hematoflow Analysis
Reference Values for WBC Differential by Hematoflow Analysis Open
These normal values will be helpful in the definition of relevant threshold for the automatic validation of samples analyzed by flow cytometry and the flagging of pathologic samples.
View article: Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation
Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation Open
View article: A case of acute promyelocytic leukaemia with unusual cytological features and a <i><scp>ZBTB</scp>16‐<scp>RARA</scp></i> fusion gene
A case of acute promyelocytic leukaemia with unusual cytological features and a <i><span>ZBTB</span>16‐<span>RARA</span></i> fusion gene Open
We report the case of a 50-year-old man who was hospitalized for investigation of a painful knee associated with high fever. Haematological tests showed platelets 326 × 109/l, haemoglobin concentration 90 g/l and neutrophils 1·3 × 109/l wi…